TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03854006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
Study: NCT00829751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision lenses soaked in ReNu Multiplus
Description: Purevision silicone hydrogel lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision lenses soaked in OptiFree RePlenish
Description: Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
Study: NCT01979913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
Study: NCT02160106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Study: NCT02341924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portfolio of functional foods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control foods
Study: NCT01751724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Description: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
Study: NCT02584153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Microparticles
Description: Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
Study: NCT01705249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Description: After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
Study: NCT03942042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT00156117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5 mg BID or 10mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01474915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: Subject will receive 25 mg of Promethazine IV around anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: Subject will receive 25 mg of Promethazine IV around anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Subject will receive 10 mg of Dexamethasone IV around anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
Study: NCT01636934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
Study: NCT03916978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP intra ovarian infusion
Description: Autologous PRP intra ovarian infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous PFP intra ovarian infusion
Description: Autologous PFP intra ovarian infusion
Study: NCT02431845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
Study: NCT04084288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulator
Description: Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
Study: NCT04421768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cervical exam training
Description: Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cervical exam training
Description: Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
Study: NCT02587403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fortiva™ Porcine Dermis
Description: Fortiva Porcine Dermis implantation during repair of complex ventral hernia
Study: NCT00156117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 15 mg QD
Study: NCT02168361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2b
Description: 1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
Study: NCT02587403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Strattice tissue matrix implanted during repair of complex ventral hernia
Study: NCT01674140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: goserelin acetate
Description: Given subcutaneously or intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously or intramuscularly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study: NCT02168361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 12 weeks of combination sofosbuvir and simeprevir
Study: NCT01674140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leuprolide acetate
Description: Given subcutaneously or intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given subcutaneously or intramuscularly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT00098475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study: NCT01661543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beans
Description: 120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (rice)
Description: 110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
Study: NCT01636934

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
Study: NCT04231409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Spectra WaveWriter SCS System
Description: The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
Study: NCT02168361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: 12 weeks of combination sofosbuvir and simeprevir
Study: NCT03800667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 1000 MG
Description: 1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
Study: NCT00111020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
Study: NCT03037502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)
Description: Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
Study: NCT03693742

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT scan
Description: Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 18F-DCFPyL PET/CT scan
Description: Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSG drink
Description: Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
Study: NCT00329732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivicaine and 2% lidocaine
Description: The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: matching volume of saline (placebo)
Study: NCT04111887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
Study: NCT01214343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib with Low-dose FP
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
Study: NCT02543580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric acupoint stimulation
Description: electrodes are attached o the skin and electric stimulation is given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric acupoint stimulation
Description: electrodes are attached o the skin and electric stimulation is given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrode attached but no stimulation
Description: electrodes are attached o the skin but no stimulation is given
Study: NCT02834039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume 6 ml/kgBW
Description: Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume 10 ml/kgBW
Description: Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
Study: NCT02051686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive a similar volume load of normal saline and maintenance doses.
Study: NCT02304718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stationary bike
Study: NCT03159221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BFST for Teens with Type 2 Diabetes
Description: BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
Study: NCT01601730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil and Escitalopram
Description: Treatment 4: Modafinil 200 mg + Escitalopram 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Treatment 2: Modafinil 200 mg + Escitalopram 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Treatment 3: Modafinil 0 + Escitalopram 20 mg.
Study: NCT04449601

Intervention type: OTHER
Intervention: clinical assesment
Description: Comparison of Hypertensive group and normotensive group

Intervention type: OTHER
Intervention: clinical assesment
Description: Comparison of Hypertensive group and normotensive group
Study: NCT01661543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peas
Description: 120 grams of peas will be consumed 5 out of 7 days per week
Study: NCT01445275

Intervention type: PROCEDURE
Intervention: Evaluation of Cancer Risk Factors
Description: Ancillary studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Ancillary study

Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Ancillary studies
Study: NCT03680092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus per institutional guidelines
Study: NCT04470011

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Intervention type: OTHER
Intervention: Interviews with service providers
Description: Clinicians and lay staff will be interviewed regarding the ART initiation process.